Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Hydrogen Gas Inhalation Alleviates Radiation-Induced Bone Marrow Damage in Cancer Patients
16 Pages Posted: 11 Mar 2019More...
Background: Radiotherapy for cancer patients is one of the useful methods; however, it not only impairs the targeted tumor tissues but also damage the normal surrounding tissues. Intensity modulated radiation therapy (IMRT) for cancer patients has been recently performed to alleviate the adverse effects, but reducing bone marrow damage is limited in the patients with multiple tumor lesions and large irradiation volume. Molecular hydrogen (H2) was recently reported as a preventive and therapeutic antioxidant that selectively scavenges hydroxy radical (*OH) and peroxynitrite (ONOO-). This observational study aims to examine whether H2 gas treatment improves IMRT radiation-induced bone marrow damage in cancer patients.
Methods: The patients with end stage of cancer were received IMRT once per day for 1 to 4 weeks except Saturday and Sunday. After each IMRT, the patients of control group (n = 7) were housed in health care chamber (HCC, mild hyperbaric oxygen chamber) for 30 minutes, and the patients of H2 group (n = 16) were also housed in HCC and received 5% H2 gas for 30 minutes once per day. Radiation-induced bone marrow damage was evaluated by hematological examination of peripheral blood obtained before and after IMRT.
Results: IMRT with HCC therapy significantly reduced white blood cells (WBC) and platelets (PLT) respectively, but not red blood cells (RBC), hemoglobin (HGB) and hematocrit (HT). In contrast, H2 gas treatment significantly alleviates reducing effects of WBC and PLT respectively. There was no difference in anti-tumor effects between the two groups.
Interpretation: Our study demonstrated that H2 gas inhalation therapy significantly alleviates IMRT radiation-induced bone marrow damage without compromising anti-tumor effects. These results suggest that H2 gas treatment would be a strategy for reducing IMRT bone marrow damage in cancer patients.
Declaration of Interest: NI and ST are supported by a grant from MiZ Company Limed. The other authors declare that they have no competing interests.
Ethical Approval: The study protocol and materials were approved by ethics committee review by ICVS Tokyo Clinic (Tokyo, Japan), and all subjects provided written informed consent prior to the therapy.
Suggested Citation: Suggested Citation